Newsroom

Sorted by: Latest

-

OBERON AIM VCT PLC UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  13 November 2026 OBERON AIM VCT PLC (the “Company”) TRANSACTION IN OWN SHARES The Board of Oberon AIM VCT plc announces that on 12 November 2026 the Company purchased for cancellation 100,000 ordinary shares of 10p each (“Ordinary Shares”) at a gross price of 18.75 pence per share. In accordance with the FCA's Disclosure Guidance and Transparency Rules sourcebook transitional provision 6, the Company advises that, following this purchase, its share capital consists of...
-

Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media

HAMAMATSU, Japan--(BUSINESS WIRE)--Yamaha Corporation announced an agreement to acquire Disguise, a London-based provider of software and media server technologies for live experiences....
-

Kaleon's Board of Directors Expresses Its Deepest Condolences on the Passing of Chairman Vitaliano Borromeo and Appoints Giberto Borromeo Arese Borromeo as the New Chairman of the Board of Directors

MILAN--(BUSINESS WIRE)--Regulatory News: Kaleon S.p.A. (Paris:ALKLN) (MIL:KLN) (“Kaleon” or the “Company”), a company affiliated with the Borromeo family, specialising in the management and enhancement of significant artistic, natural and museum heritage assets for tourism purposes, announces that the Company’s Board of Directors met today and adopted the resolutions set out below. Passing of Chairman Vitaliano Borromeo and appointment of the new Chairman of the Board of Directors The Board of...
-

LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China...
-

Le conseil d'administration de Kaleon exprime ses plus profondes condoléances à la suite du décès de son président, Vitaliano Borromeo Arese Borromeo, et nomme Giberto Borromeo Arese Borromeo nouveau président du conseil d'administration

MILAN--(BUSINESS WIRE)--Regulatory News: Kaleon S.p.A. (Paris:ALKLN) (MIL:KLN) (“Kaleon” ou la “Société”), société liée à la famille Borromeo et spécialisée dans la gestion et la valorisation de patrimoines artistiques, naturels et muséaux à vocation touristique, annonce que le Conseil d'administration de la société s'est réuni ce jour et a adopté les décisions présentées ci-après. Décès du président Vitaliano Borromeo et nomination du nouveau président du conseil d'administration Le Conseil d'...
-

Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 12 November 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 12 November 2026 Number of Public Shares Purchased:...
-

Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype h...
-

Republic Technologies Announces 2026 AGSM Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (the “Company” or “Republic”) is pleased to announce that all matters put forth at the Company’s Annual General and Special Meeting of Shareholders (the “Meeting”) held on November 12, 2026 were approved by its shareholders. The Company’s shareholders voted to fix the number of directors of the Company at four and elected the following four nominees to the board of directors: Daniel Liu, Hongming Lu...
-

vVARDIS Announces Pricing of Initial Public Offering

ZUG, Switzerland--(BUSINESS WIRE)--vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The C...
-

FreeCast Thanks Bill Jennings for His Board Service

ORLANDO, Fla.--(BUSINESS WIRE)--FreeCast, Inc. (NASDAQ: CAST), a provider of white-label streaming and media monetization software, today expressed its appreciation to departing director Bill Jennings for his service and commitment to the Company. His departure was effective November 6, 2026. “On behalf of FreeCast and our Board, I thank Bill for his dedication and contributions,” said William Mobley, Founder and CEO of FreeCast. “We appreciate his service and wish him continued success.” FreeC...